Roche expands Global Access Program to include the first fully automated CE marked nucleic acid HIV-1/HIV-2 qualitative diagnostic test.
Sunday, 10 September 2017
Differentiates between HIV-1 and HIV-2 infections to confidently treat patients based on HIV subtype infection – Significant reduction in time to detection is critical in curbing further disease transmission – Access to testing in rural areas through validated dried blood spot (DBS) collection card PLEASANTON, California, July 25, 2017 /PRNewswire/ — Roche
- Published in Health & life sciences
No Comments